Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AD
Adagene Inc. American Depositary Shares
ADAG
Mkt Cap
$138.0M
Volume
376.94K
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
AD
ADAG
AD
Adagene Inc. American Depositary Shares
ADAG
News
·
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
Mkt Cap
$161.1M
Volume
376.94K
Next Earnings
N/A
Chart
Financials
Earnings
News
About
Insider
Filings
Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update
Adagene reported 29% overall response rate for muzastotug (ADG126) in MSS colorectal cancer patients at the 20 mg/kg dose, with median overall survival of 19.4 months at 10 mg/kg dose. The company demonstrated improved tolerability with 4% discontinuation rate and no Grade 4-5 adverse events across 67 patients. With $74.5 million in cash as of December 31, 2025, Adagene expects runway into early 2028 and plans to initiate a registration trial once optimal dose is established.
GlobeNewswire Inc. · Apr 1, 2026
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Adagene has signed a licensing agreement with Third Arc Bio to utilize its SAFEbody technology platform for developing two masked CD3 T cell engagers targeting unique tumor-associated antigens. The deal includes an upfront payment of $5 million and potential milestone payments up to $840 million.
GlobeNewswire Inc. · Nov 13, 2025
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Adagene initiated a Phase 2 clinical trial for muzastotug (ADG126) in combination with KEYTRUDA for microsatellite stable colorectal cancer, randomizing patients to 10 or 20 mg/kg doses with anticipated trial completion in early 2027.
GlobeNewswire Inc. · Oct 31, 2025
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China
Adagene will present results of ADG126, a masked anti-CTLA-4 therapy, at the Chinese Society of Clinical Oncology meeting, showcasing promising outcomes in treating microsatellite stable colorectal cancer with an objective response rate of ~30%.
GlobeNewswire Inc. · Sep 5, 2025
Adagene Announces Regulatory Update on Clinical Development Plan for Muzastotug in Microsatellite Stable Colorectal Cancer Following Productive Type B (End of Phase 1) Meeting with FDA
Adagene received FDA feedback on its clinical development plan for muzastotug (ADG126), an anti-CTLA-4 therapy for microsatellite stable colorectal cancer, with plans to begin Phase 2 patient enrollment in 2H 2025.
GlobeNewswire Inc. · Jul 15, 2025
Adagene announces up to $25 million strategic investment from Sanofi
Sanofi will invest up to $25 million in Adagene, exercise an option on a third SAFEbody discovery program, and sponsor a combination clinical trial for muzastotug in advanced solid tumors. The investment is expected to extend Adagene's cash runway into 2027.
GlobeNewswire Inc. · Jul 1, 2025
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
Adagene, a biotechnology company, announced its presentation at the 11th Annual Immuno-Oncology 360⁰ Summit in Boston on March 26, 2025. The presentation will focus on their lead clinical program, ADG126, a masked anti-CTLA-4 SAFEbody that targets regulatory T cells in the tumor microenvironment.
GlobeNewswire Inc. · Mar 13, 2025
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene presented data on its masked anti-CTLA-4 antibody ADG126, showing improved safety and efficacy profiles compared to ipilimumab, and positive results in combination with pembrolizumab for advanced metastatic microsatellite-stable colorectal cancer.
GlobeNewswire Inc. · Nov 7, 2024
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Adagene, a biotechnology company, announced upcoming poster presentations on its masked anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at the SITC 39th Annual Meeting. The presentations will focus on the improved clinical therapeutic index of Muzastotug and its combination with anti-PD-1 therapy in advanced/metastatic microsatellite-stable colorectal cancer.
GlobeNewswire Inc. · Oct 9, 2024
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 - GlobeNewswire
Adagene announced a poster presentation at the upcoming ESMO Congress on the results of an ongoing phase 1b/2 trial of its masked anti-CTLA-4 SAFEbody ADG126 in combination with pembrolizumab for metastatic microsatellite-stable colorectal cancer.
GlobeNewswire Inc. · Jul 12, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
AD
ADAG
Adagene Inc. American Depositary Shares
Buy
Sell
Market
Limit
Soon
ADAG
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any ADAG yet.
Related Tickers
Earnings